The expression level of SLC2A3 is higher in tumors such as kidney renal clear cell carcinoma (KIRC), pancreatic adenocarcinoma (PAAD), and testicular germ cell tumors (TGCT), compared to the matching healthy tissues (Fig. 5F) [43], indicating these patients with higher SLC2A3 expression might also benefit from doxorubicin containing regimen. The gene discussed is SLC2A3; the disease is pancreatic adenocarcinoma.